Results 101 to 110 of about 26,835 (181)

Novel transferosome formulation of Vemurafenib for skin cancer management: biocompatible and scalable strategies

Beni-Suef University Journal of Basic and Applied Sciences
Due to challenges such as poor aqueous solubility and compromised oral bioavailability, delivering Vemurafenib via a topical route using a scalable and biocompatible carrier-based hydrogel.
Tariq M. Aljarba, Aftab Alam, Ahmed Farag El Kirdasy   +2 more
doaj   +1 more source

Cutaneous side-effects during therapy of melanoma by vemurafenib

Przegląd Dermatologiczny, 2015
Introduction. Vemurafenib is a selective inhibitor of serine-threonine kinase BRAF used in the treatment of advanced melanoma with BRAF mutation. Effectiveness of this drug was confirmed in a large clinical trial, which led to the increase of its ...
Anna Ankudowicz, Urszula Brzezicka-Ciach, Bożena Wenska   +2 more
doaj   +1 more source

Mechanisms of vemurafenib-induced anti-tumor effects in ATC FRO cells

Heliyon
Background: Anaplastic Thyroid Carcinoma (ATC) is a rare and deadly malignant tumor in humans. It is prone to developing resistance to radiotherapy and chemotherapy. Molecular targeted therapy offers a novel way to treat ATC. The BRAF mutation is closely
Jingwei Xu, Di Xue, Yang Li, Jianwen Zhou, Hongyue Chen, Li Fan   +5 more
doaj   +1 more source

Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature

Cancer Reports
Background Langerhans cell histiocytosis (LCH) is a clonal myeloid neoplasm with inflammatory component. Refractory disease is a challenge, but vemurafenib has emerged as a therapeutic option.
Klerize Anecely de Souza Silva, Isis Maria Quezado Soares Magalhães, Daniela Elaine Roth Benincasa, Daiane Keller Cecconello, Mariana Bohns Michalowski   +4 more
doaj   +1 more source

MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX). [PDF]

, 2017
A pancreatic ductal adenocarcinoma (PDAC), obtained from a patient, was grown orthotopically in the pancreatic tail of nude mice to establish a patient-derived orthotopic (PDOX) model.
Bouvet, Michael, Clary, Bryan M, Delong, Jonathan C, Hoffman, Robert M, Hwang, Ho Kyoung, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Lwin, Thinzar M, Murakami, Takashi, Unno, Michiaki   +10 more
core  

Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation

Case Reports in Oncological Medicine, 2016
Introduction. BRAF kinase inhibitors such as Vemurafenib have shown improvement in overall survival, progression-free survival, and response rates in patients with metastatic melanoma with BRAF V600K mutation.
K. Sahadudheen, Md. Rafiqul Islam, M. Iddawela   +2 more
doaj   +1 more source

Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. [PDF]

, 2019
Despite being one of the most common cancers, treatment options for prostate cancer are limited. Novel approaches for advanced disease are needed. We evaluated the relative rate of use of clinical-grade next generation sequencing (NGS) in prostate cancer,
Carter, Jennifer L, Elkin, Sheryl K, Ikeda, Sadakatsu, Kurzrock, Razelle, Tomson, Brett N   +4 more
core  

Novel mechanisms of resistance to vemurafenib in melanoma – V600E B-Raf reversion and switching VEGF-A splice isoform expression [PDF]

, 2014
Targeting activating mutations in the proto-oncogene B-Raf, in melanoma, has led to increases in progression free survival. Treatment with vemurafenib, which inhibits the most common activating-mutated form of B-Raf (B-RafV600E), eventually results in ...
Bates, DO, Beazley Long, N, Gaston, Kevin, Harper, S J, Orlando, A   +4 more
core   +1 more source

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma. [PDF]

Clin Cancer Res
Dummer R, Deng S, Xie T, Pathan N, Saffari H, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandala M, Schadendorf D, Yamazaki N, Ascierto PA, Davis CB, Shah K, Hamilton P, di Pietro A, Flaherty K.   +22 more
europepmc   +1 more source

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations. [PDF]

Mol Biomed
Shang Y, Cao T, Li J, Li J, Zhang L, Ma Q, Feng L, Zhao H.   +7 more
europepmc   +1 more source